Structural racism and AML survival, promoter competition and hemoglobin switching, and CAR T-cell therapy and high-risk cytogenetics in ALL

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Press Pass | Lawrence on Prep for Patriots' Run Defense, Responding & Building Trust 11 min · 23 Sep 2026 · The Jacksonville Jaguars Official Podcast Network

Iran Enters the War of Words; The AI Agenda for the Trump-Xi Summit 26 min · 23 Sep 2026 · Here's the Scoop

Trump vs. the media 21 min · 23 Sep 2026 · The NPR Politics Podcast

Trump meets Xi: what's at stake? 19 min · 23 Sep 2026 · Business Daily

Musings About the Agentic Future 22 min · 23 Sep 2026 · Motley Fool Hidden Gems Investing

The Reign of Spain 54 min · 23 Sep 2026 · Football Daily

Report any issue

Source

Recorded07 Apr 2022

Publisherfeeds.transistor.fm ↗

Handlerec:11742092

Show notes

In this week’s episode we’ll first cover a research article demonstrating the striking contribution of neighborhood disadvantage to racial and ethnic disparities in survival in patients with acute myeloid leukemia. The second research article provides a model for understanding how disruption of the adult-globin promoter may alleviate promoter competition, thereby reactivating fetal gamma-globin gene expression. We will close with a research article showing that CD19-directed CAR T-cell therapy provides durable remissions in patients with relapsed or refractory ALL across cytogenetic categories, including those patients with high-risk cytogenetics.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in